Search
Vyne Therapeutics Inc
VYNEAdd to Watchlist
28.560USD
0.0000.00%
Close 07-27 16:00（ET）Quotes delayed by 15 min
18.71MMarket Cap
LossP/E TTM
More Details of Vyne Therapeutics Inc Company
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc Info
Ticker SymbolVYNE
Company nameVyne Therapeutics Inc
IPO dateJan 25, 2018
CEODomzalski (David)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 25
Address685 Route 202/206 N., Suite 301
CityBRIDGEWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08807
Phone18007757936
Websitehttps://vynetherapeutics.com/
Ticker SymbolVYNE
IPO dateJan 25, 2018
CEODomzalski (David)
Company Executives of Vyne Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
97.44K
-3.55%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.49K
-3.92%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
52.11K
-6.65%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
97.44K
-3.55%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.49K
-3.92%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
52.11K
-6.65%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of Vyne Therapeutics Inc?
The top five shareholders of Vyne Therapeutics Inc are: Mr. Tyler Zeronda
How many institutions hold shares of Vyne Therapeutics Inc (VYNE)?
As of 2026Q1, 92 institutions hold shares of Vyne Therapeutics Inc, with a combined market value of approximately 11.08M, accounting for 33.26% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1672969.00.